ESMO 2023 | The influence of HRD testing in precision medicine

Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, discusses how homologous recombination deficiency (HRD) testing in patients with ovarian carcinoma fits into the wider landscape of precision medicine. Dr You explains how it is a beneficial aspect in furthering our understanding of the disease and its availability to patients who are HRD-positive is imperative in improving overall survival, particularly with targeted therapies such as olaparib and bevacizumab as in the PAOLA-1 trial (NCT02477644). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.